Abstract
Biopsies are currently utilized for profiling (histologic, molecular) of lung cancer prior to treatment. Profiling tumors from circulating markers could avoid invasive procedures and enable more frequent, kinetic disease monitoring. PD-L1 expression on lung cancer biopsy correlates with efficacy of immune checkpoint inhibitors. Using the Epic Sciences PD-L1 assay, we sought to correlate patient outcome with PD-L1(+) circulating CD45(-) cells, prior to its evaluation as a predictive biomarker for immune checkpoint inhibitors. Peripheral blood was collected from 124 pts with diverse staging and histology at three clinical sites prior to diagnostic biopsy, with some having follow-up draws. All nucleated cells were plated onto glass slides and circulating cells of interest identified by immunofluorescence and morphological features. Prognostic capacity of PD-L1(+) cells (CK + /-, CD45-, PD-L1 + , malignant nuclear morphology) were assessed with Kaplan-Meier and Cox Proportional Hazard (PH) models. Results:Tabled 1AJCC Stagen = 124 Baselinen = 27 Follow-UpI537II184III308IV228 Open table in a new tab When detected, PD-L1 subcellular localization was primarily membranous. Pts with >1 PD-L1(+) cell/mL in baseline samples had worse overall survival (OS) (n = 22/124, mOS: 17.2 months vs. not reached, HR = 3.22, p = 0.0015) and follow-up (n = 5/22 mOS = 2.1 months vs. not reached, HR = 4.25, p = 0.0302). High baseline PD-L1(+) cell burden was additive and independent to AJCC staging in Cox PH models (HR = 2.32, p = 0.0447). Single-cell sequencing is underway. In a multicenter cohort, circulating PD-L1(+)/CD45(-) cell burden predicted worse OS in pre-biopsy and follow-up lung cancer blood samples. This warrants prospective investigation as a predictive biomarker to PD-1 axis immune checkpoint inhibitors.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
